| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF5 |
| Uniprot No | P25942 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-193aa |
| 氨基酸序列 | EPPTACREKQYLINSQCCSLCQPGQKLVSDCTEFTETECLPCGESEFLDTWNRETHCHQHKYCDPNLGLRVQQKGTSETDTICTCEEGWHCTSEACESCVLHRSCSPGFGVKQIATGVSDTICEPCPVGFFSNVSSAFEKCHPWTSCETKDLVVQQAGTNKTDVVCGPQDRLR |
| 预测分子量 | 48.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TNFRSF5(CD40)重组蛋白的3篇代表性文献摘要：
---
1. **文献名称**: *CD40 and its ligand in cell-mediated immunity*
**作者**: Banchereau, J. et al.
**摘要**: 研究揭示了重组CD40蛋白与其配体(CD40L)在B细胞激活中的关键作用，证实CD40信号可促进B细胞增殖、抗体类别转换及生发中心形成，为免疫调节奠定理论基础。
---
2. **文献名称**: *CD40 agonist antibodies in cancer immunotherapy*
**作者**: Vonderheide, R.H.
**摘要**: 评估重组CD40激动剂抗体在实体瘤模型中的效果，证明其通过激活抗原呈递细胞和增强T细胞应答显著抑制肿瘤生长，推动CD40靶向疗法进入临床试验。
---
3. **文献名称**: *Structural basis of CD40 signaling via TRAF proteins*
**作者**: Ni, C.Z. et al.
**摘要**: 通过X射线晶体学解析重组CD40胞内段与TRAF蛋白复合物结构，阐明CD40通过特定结构域招募TRAF2/3/5以激活下游NF-κB和MAPK信号通路的分子机制。
---
这些研究分别从功能机制、治疗应用及结构基础角度解析了CD40重组蛋白的生物学意义。
**Background of TNFRSF5 Recombinant Protein**
TNFRSF5. also known as CD40 or CD40 antigen, is a cell-surface receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). It plays a pivotal role in adaptive immunity by mediating interactions between antigen-presenting cells (e.g., B cells, dendritic cells) and CD40 ligand (CD40L/CD154)-expressing T cells. CD40 activation triggers signaling pathways (e.g., NF-κB, MAPK) that regulate B-cell proliferation, antibody class switching, germinal center formation, and T-cell priming. Dysregulation of CD40 signaling is linked to autoimmune diseases, chronic inflammation, and cancer.
Recombinant TNFRSF5 protein is engineered *in vitro* using expression systems like mammalian cells (e.g., HEK293. CHO) or *E. coli*, often modified to enhance solubility and stability (e.g., Fc fusion tags). This protein typically retains the extracellular domain responsible for ligand binding, enabling functional studies of CD40-CD40L interactions. Applications include *in vitro* assays to dissect immune signaling mechanisms, drug screening for CD40-targeted therapies (e.g., agonists for cancer immunotherapy, antagonists for autoimmune disorders), and as an immunogen for antibody development.
In therapeutic contexts, CD40-targeted biologics are explored to modulate immune responses. For example, CD40 agonists may enhance anti-tumor immunity by activating dendritic cells, while antagonists could suppress aberrant inflammation in autoimmune conditions. However, balancing efficacy and toxicity (e.g., cytokine release syndrome) remains a challenge. Structural studies using recombinant TNFRSF5 have also aided in mapping binding epitopes and designing next-generation immunotherapies. Overall, TNFRSF5 recombinant protein serves as a critical tool for advancing both basic immunology research and translational drug development.
×
